Page Redirect Alert
The link you are about to visit does not belong to this site, please pay attention to your account security.
https://cts.businesswire.com/ct/CT?id=smartlink&url=https://www.catalym.com/catalym-demonstrates-clinical-efficacy-and-tolerability-in-first-in-human-phase-1-trial-for-visugromab-and-nivolumab-combination/&esheet=53468510&newsitemid=20230720231828&lan=en-US&anchor=announced in September 2022&index=3&md5=04cd20c34e2d6a147d6ab77de230495e
